Status:
COMPLETED
A Study to Collect Information on the Characteristics of Elderly Belgian Patients With NVAF That Are Treated With a NOAC for This Indication With a Special Focus on Their Fear of Bleeding While Using a NOAC vs the Clinical Benefit of a NOAC of Thrombosis/Stroke Prevention.
Lead Sponsor:
Bayer
Conditions:
Non-Valvular Atrial Fibrillation
Eligibility:
All Genders
75+ years
Brief Summary
Atrial fibrillation is a heart condition that causes an abnormal and fast heart rate. For people with non-valvular atrial fibrillation (NVAF), this is caused by problems such as high blood pressure an...
Eligibility Criteria
Inclusion
- Male or female elderly patients (defined as ≥ 75 years old) diagnosed with NVAF
- Elderly patients treated with a NOAC
- Ambulatory patients visiting the geriatrician
Exclusion
- Contra-indications according to the local marketing authorization
- Patients suffering from dementia who are, according to the geriatrician's opinion, not able to understand and answer the questions
- Hospitalized patients
Key Trial Info
Start Date :
May 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 3 2022
Estimated Enrollment :
103 Patients enrolled
Trial Details
Trial ID
NCT04722679
Start Date
May 11 2021
End Date
January 3 2022
Last Update
March 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, Belgium